HeartFlow reported third-quarter revenue of $72.9 million, up 57% year-over-year, and raised 2026 revenue guidance to $262 million to $264 million, representing 49% to 50% growth. Non-GAAP gross margin reached 83.8%, and cash flow profitability is expected by mid-2028.
HTFL · Heartflow, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 49%
- Last earnings
- Nov 12, 2026
- Latest filing
- 10-Q · Nov 12
- Price history
- Aug 2025 to Nov 2026
Up next
Latest documents
Heartflow reported revenue of $72.9 million for three months ended September 30, 2026, up 57%, with gross margin at 84% and net loss narrowing to $11.5 million from $50.9 million.
Heartflow reported third-quarter 2026 revenue of $72.9 million, up 57% year-over-year, and raised 2026 revenue guidance to $262 million to $264 million from $246 million to $250 million; non-GAAP gross margin guidance increased to approximately 82.5% from approximately 82%.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 12, 2026TL;DR. Heartflow delivered 57.4% revenue growth, raised full-year revenue and gross-margin guidance, expanded plaque coverage, and increased confidence in mid-2028 cash flow profitability. It nevertheless remained loss-making, with operating expenses above revenue, while fourth-quarter plaque pricing was expected to be flat and the company disclosed commercialization, reimbursement, AI, regulatory, and competitive risks.
- + Third-quarter total revenue grew 57.4% to $72.9 million, with U.S. revenue up 60% to $67.9 million. new
- + Full-year revenue guidance was raised to $262 million–$264 million, representing 49%–50% growth. new
- + Full-year non-GAAP gross margin guidance was raised to approximately 82.5%. new
- + Third-quarter non-GAAP gross margin improved to 83.8% from 76.8% a year earlier. new
- + Plaque payer coverage increased to approximately 82% of U.S. lives. new
- + Management increased its confidence in achieving cash flow profitability by mid-2028. new
- − The company remained GAAP operating-loss-making in the third quarter, with a $13.8 million operating loss. new
- − The company reported a third-quarter GAAP net loss of $11.5 million, or $0.13 per share. new
- − Third-quarter operating expenses were 103% of revenue, continuing to exceed revenue. new
- − Plaque pricing is expected to be roughly flat sequentially in the fourth quarter. new
- − Plaque commercialization remains nascent, while reimbursement shortfalls could negatively affect platform adoption. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -23.96M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| annotated CTA images | 250M | November 12, 2026 | — |
| coronary CTA image acceptance rates | 97% | November 12, 2026 | — |
| Gross margin non-GAAP | 82.7% | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Heartflow revenue cases | 98,155 | the three months ended September 30, 2026 filing | — |
|
|
|||
| institutions globally | 1,800 | November 12, 2026 | — |
| Non-GAAP gross margin non-GAAP | 83.8% | Third Quarter 2026 | — |
| patients | 365,000 | November 12, 2026 | — |
| patients worldwide | 800,000 | November 12, 2026 | — |
| Stock-based compensation costs (personnel and related expenses) | $4.7M | the three months ended September 30, 2026 filing | — |
| studies | 200 | November 12, 2026 | — |
| The percentage of our U.S. revenue cases attributable to office and clinic-based accounts | 36% | the three months ended September 30, 2026 filing | — |
| Loss from operations non-GAAP | -$22.98M | Six Months Ended June 30, 2026 | — |
| Net loss non-GAAP | -$18.69M | Six Months Ended June 30, 2026 | — |
| Net loss per share, basic and diluted non-GAAP | -$0.22 | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HTFL
this stock
Heartflow, Inc.
|
$3.92B | +53.1% | +39.9% | — | 6.5% |
|
VEEV
Veeva Systems Inc
|
$42.57B | +17.8% | +28.1% | 43.0 | 2.4% |
|
PMDIY
Pro Medicus Ltd.
|
$14.81B | -14.6% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$12.74B | +70.9% | +28.2% | 34.8 | 5.8% |
|
TEM
Tempus AI, Inc.
|
$10.87B | +0.9% | +83.4% | — | 13.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 12, 2026
- This year
- 15
Heartflow reported revenue of $72.9 million for three months ended September 30, 2026, up 57%, with gross margin at 84% and net loss narrowing to $11.5 million from $50.9 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HTFL | -25.5% | -19.5% | +44.0% | -24.4% | +53.1% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -20.1% | -13.2% | +49.6% | -19.2% | +48.1% |